Capricor Therapeutics (CAPR) Receives FDA Rejection of Deramiocel Application
Capricor Therapeutics (CAPR) received an FDA rejection for its Deramiocel application, citing insufficient evidence. The company has $198.5M in cash, funding at least 12 months of operations. The FDA's Complete Response Letter is a setback for Capricor's lead candidate, and the company will assess next steps.
How this was made

The 30-second read
Why it matters
The FDA CRL represents a material regulatory setback, likely prompting short‑term price decline and heightened volatility.
Market read
Regulatory outcome directly affects CAPR's valuation and may influence peer biotech stocks awaiting FDA decisions.
What to watch
The company's cash runway of $198.5M may allow continued development without immediate financing pressure.
Background
Capricor Therapeutics (CAPR) is a Nasdaq‑listed biotech focused on cell‑based therapies. The Deramiocel candidate targets a rare disease indication.
Ticker impact
FDA issued a Complete Response Letter rejecting Capricor Therapeutics' Deramiocel application, citing insufficient efficacy evidence.
likely pressure as the market prices in the FDA denial
Regulatory denials for biotech candidates typically trigger immediate sell‑offs, especially for cash‑burning microcaps.
Market effects
May dampen sentiment for late‑stage biotech pipelines and increase scrutiny on similar cell‑therapy candidates.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If Capricor can quickly address FDA concerns, the stock could rebound on a potential resubmission.
Key entities
- CompanyCapricor Therapeutics
Biotech firm developing Deramiocel.
- RegulatorU.S. Food and Drug Administration
Issued the Complete Response Letter rejecting the application.


